Pharma frets over CDER chief Woodcock's retirement; Vivus study finds Qsymia helped stave off diabetes;

@FiercePharma: Top 10 Drugmakers in Emerging Markets--our latest special report. Feature | Follow @FiercePharma

@CarlyHFierce: Teva: Copying GlaxoSmithKline's Advair too tough for success before 2018. ICYMI yesterday | Follow @CarlyHFierce

> As FDA bigwig Dr. Janet Woodcock prepares to retire next year, drugmakers are worrying about who will replace her. Report

> Vivus ($VVUS) said high-risk patients who used its weight loss drug Qsymia were more than 70% less likely to develop diabetes, compared with patients on placebo. Report

> A federal judge rejected two drugmakers' move to keep secret their reports submitted to the federal government to comply with corporate integrity agreements. Report

> The generic drugmaker Lannett closed its public stock offering, which delivered net proceeds of $71.5 million. Report

> The state of Missouri said it would return an anesthetic it planned to use in executions after its manufacturer, Germany's Fresenius Kabi, protested. Report

> Fitch Ratings figures biosimilars uptake will be stronger in the U.S. than it has been in Europe, though acceptance may be slow at first. Report

Medical Device News

@FierceMedDev: Medtronic jumps into hemodialysis business through India partnership. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: The head of Roche molecular diagnostics spoke to FierceDiagnostics recently about two key future products. More | Follow @MarkHFierce

@MichaelGFierce: Check out this week's FierceDrugDelivery newsletter! RNAi roundup & stem cell drug delivery action. Report | Follow @MichaelGFierce

> Are medical device companies invited to the biotech IPO party? Editor's corner

> Boston Scientific kicks off drug-eluting stent trial as sales wane. Story

> Quest warns reimbursement pressures, test volume declines will dampen Q3. More

> FDA panel casts doubt on CardioMEMS' heart failure diagnostic. Article

Biotech News

@FierceBiotech: Popular yesterday: 10 top drugs in biopharma's late-stage pipeline. Feature | Follow @FierceBiotech

@JohnCFierce: Few months after $60M C series and Forest deal, Trevena files for $86M IPO. SEC filing | Press release | Follow @JohnCFierce

@DamianFierce: MacroGenics has up-sized its IPO, now seeking $80M amid biotech blitz. ICYMI yesterday | Follow @DamianFierce

@EmilyMFierce: 3-D printing builds bacterial metropolises. More via ScienceNews | Follow @EmilyMFierce

> Google visionaries ready to invest a fortune in revolutionizing aging process. Article

> Takeda punts $620M antibody licensing pact with Immunomedics. Story

> Gilead scores early PhIII success for idelalisib in chronic lymphocytic leukemia. More

Pharma Manufacturing News

@EricPFierce: Will McKesson and AmerisourceBergen now face off in Europe? Article | Follow @EricPFierce

> Catalent moves on Brazil VMS, softgel market. News

> Vetter putting $100M into its production network. Report

> Teva looks for big savings from procurement, manufacturing. Story

> Feds fight drug imports Maine now allows. More

> BioCentury finds FDA has $270M in GDUFA, PDUFA fees in hand. Item

Vaccines News

> WHO prequalification moves China into global vaccine arena. Item

> Novartis opening vaccine R&D lab in North Carolina. Report

> Takeda's norovirus vaccine misses endpoint in early-phase trial. Story

> GSK targets 2015 launch for malaria vaccine. Article

> HIV trial follow-up quashes fears of infection risk. More

And Finally... Can peanut butter help diagnose Alzheimer's disease? Report

Suggested Articles

UnitedHealthcare will stop covering Descovy in PrEP in favor of Truvada, which is on track to see low-cost generic competition in September.

AstraZeneca has signed into the EU’s first finalized COVID-19 vaccine supply agreement.  

The U.K.'s two new deals with J&J and Novavax bring its stockpile of potential COVID-19 vaccines to 340 million doses while expanding clinical trials.